Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Decoy Therapeutics says preclinical pharmacokinetic results show a single weekly intranasal dose could sustain protective exposure across upper airways and lungs for about a week; clinical trials expected to begin in 2027, with data scheduled for Sept 29 presentation.
Decoy Therapeutics said a single intranasal dose maintained drug concentrations above designed therapeutic levels for up to seven days in nasal mucosa and lung tissue, with extended tissue retention supporting prophylaxis for high-risk patients. The company expects the DCOY-CoV program to enter clinical trials in 2027.
Decoy Therapeutics reported preclinical PK data showing a single intranasal dose of DCOY-CoV maintained drug levels above designed therapeutic concentrations in nasal mucosa and lung tissue for up to 7 days. The program is expected to enter clinical trials in 2027.Material DetailsContext by AI Anal…
TradeXchange Newsdesk says Decoy Therapeutics (DCOY) reported preclinical data supporting once-weekly intranasal dosing for its DCOY-CoV program.
Once-Weekly Intranasal Potential: Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue.Addressing Endemic Coronaviruses: DCOY-CoV is designed to protect against endemic human coronaviruses (OC43…